From the Breakthroughs Blog: Guest Post
Typhoid may seem like a distant memory in industrialized countries, but for many low- and middle-income countries it continues to cause millions of illnesses and about 150,000 deaths per year. New tools are needed to combat this looming threat.
Evidence shows that when women are both empowered and healthy, they are more likely to have healthy families, educate their children, and make positive social and economic contributions to society. New discreet and long-acting HIV prevention tools have the potential to empower women to protect their own health and unlock their potential.
In this guest post, Anna Doubell, an analyst at Policy Cures, writes about the findings of this year’s G-FINDER report on neglected disease research and development (R&D). Supporting data from the report was released this week and is now available online through the G-FINDER public search tool.
Fruit-flavored drugs to saves kids’ lives: First correctly-dosed, child-friendly TB treatments developed
Early this month, GHTC member TB Alliance and its partners announced the creation of the first-ever appropriate, child-friendly tuberculosis (TB) medicine in the correct doses.
In this guest post, Dr. Monica Parise—deputy director for program and science—and Dr. Larry Slutsker—director of the Division of Parasitic Disease and Malaria—at the US Centers for Disease Control and Prevention (CDC) Center for Global Health—discuss the role of research in advancing efforts to detect, prevent, and eliminate parasitic diseases.
In this guest post, Heather Ignatius—senior policy and advocacy officer at PATH—writes about a new bipartisan piece of legislation to accelerate progress towards ending preventable child and maternal deaths.
Over the past several decades, overall investment in contraceptive R&D has declined dramatically. The result? Renewed commitment and partnerships will be required to ensure that new contraceptive methods advance through the development pipeline and that access to the final products is affordable and equitable.
I am pleased to have the opportunity to write about what is perhaps today’s most vexing public health challenge—the growing threat of antibiotic resistance.
In this guest post, Dale Halliday—an analyst at Policy Cures—discusses the finding of Policy Cures’ report on funding for reproductive health technology research and development (R&D) in developing countries.
First-ever conference devoted solely to HIV prevention R&D taking place in uncertain funding environment
Progress toward new tools to prevent HIV infection—including vaccines, microbicides, the use of antiretroviral treatment as HIV prevention, pre-exposure prophylaxis (PrEP), and a host of other options—is being presented and discussed at the inaugural HIV Research for Prevention Conference (HIVR4P) in Cape Town this week.
In this guest post, Sarah Alexander—director of external relations for the Global Alliance to Prevent Prematurity and Stillbirth (GAPPS)—writes about the groundswell of momentum surrounding maternal and child health and the role research and development (R&D) can play in helping more babies have a healthy start to life.
This post—written by Sarah Alexander, director of external relations at the Global Alliance to Prevent Prematurity and Stillbirth (GAPPS)—originally appeared in Seattle Children’s On the Pulse blog on March 5th.
In this guest post, Jaclyn Schiff—American Society of Tropical Medicine and Hygiene (ASTMH) Director of Communications—highlights news in global health research presented during the recent ASTMH Annual Meeting.
In this guest post, Emily Donaldson—program coordinator at AVAC: Global Advocacy for HIV Prevention—writes about an upcoming congressional briefing on November 18 that will highlight the latest in HIV and AIDS research and development.
In this guest post, Dr. Judy Manning from the US Agency for International Development (USAID) and Dr. Zeda Rosenberg from the International Partnership for Microbicides (IPM) discuss the need for new and improved contraceptive options for women worldwide.
Drug development is a long and complex process.
In this guest post, Dr. John Boslego, director of PATH’s Vaccine Development Global Program, writes about an innovative partnership between the United States and India to develop an oral vaccine against rotavirus diarrhea.